 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk of [0m
[34mhospitalization?[0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes METOPROLOL TARTRATE increase or decrease the risk of [0m
[32mhospitalization?[0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"METOPROLOL TARTRATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: METOPROLOL TARTRATE: pharmacokinetics: Renal Impairment The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree [0m
[31mfrom those in normal subjects. Hepatic Impairment Since the drug is primarily eliminated by hepatic metabolism, hepatic impairment may impact the pharmacokinetics of metoprolol. The elimination [0m
[31mhalf-life of metoprolol is considerably prolonged, depending on severity [0m[1;31m([0m[31mup to [0m[1;31m7.2[0m[31m h[0m[1;31m)[0m[31m. Clinical Studies Hypertension In controlled clinical studies, metoprolol has been shown to be an effective [0m
[31mantihypertensive agent when used alone or as concomitant therapy with thiazide-type diuretics, at dosages of [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg daily. METOPROLOL TARTRATE: pharmacokinetics: In controlled, comparative, [0m
[31mclinical studies, metoprolol has been shown to be as effective an antihypertensive agent as propranolol, methyldopa, and thiazide-type diuretics, to be equally effective in supine and standing [0m
[31mpositions. Angina Pectoris In controlled clinical trials, metoprolol, administered two or four times daily, has been shown to be an effective antianginal agent, reducing the number of angina attacks [0m
[31mand increasing exercise tolerance. The dosage used in these studies ranged from [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg daily. A controlled, comparative, clinical trial showed that metoprolol was indistinguishable from [0m
[31mpropranolol in the treatment of angina pectoris. METOPROLOL TARTRATE: pharmacokinetics: Myocardial Infarction In a large [0m[1;31m([0m[1;31m1[0m[31m,[0m[1;31m395[0m[31m patients randomized[0m[1;31m)[0m[31m, double-blind, placebo-controlled clinical study, [0m
[31mmetoprolol was shown to reduce [0m[1;31m3[0m[31m-month mortality by [0m[1;31m36[0m[31m% in patients with suspected or definite myocardial infarction. Patients were randomized and treated as soon as possible after their arrival in [0m
[31mthe hospital, once their clinical condition had stabilized and their hemodynamic status had been carefully evaluated. Subjects were ineligible if they had hypotension, bradycardia, peripheral signs of[0m
[31mshock, and/or more than minimal basal rales as signs of congestive heart failure. Initial treatment consisted of intravenous followed by oral administration of metoprolol or placebo, given in a [0m
[31mcoronary care or comparable unit. Oral maintenance therapy with metoprolol or placebo was then continued for [0m[1;31m3[0m[31m months. After this double-blind period, all patients were given metoprolol and followed [0m
[31mup to [0m[1;31m1[0m[31m year. METOPROLOL TARTRATE: pharmacokinetics: The median delay from the onset of symptoms to the initiation of therapy was [0m[1;31m8[0m[31m hours in both the metoprolol- and placebo-treatment groups. Among [0m
[31mpatients treated with metoprolol, there were comparable reductions in [0m[1;31m3[0m[31m-month mortality for those treated early [0m[1;31m([0m[31mâ‰¤[0m[1;31m8[0m[31m hours[0m[1;31m)[0m[31m and those in whom treatment was started later. Significant reductions in the [0m
[31mincidence of ventricular fibrillation and in chest pain following initial intravenous therapy were also observed with metoprolol and were independent of the interval between onset of symptoms and [0m
[31minitiation of therapy. In this study, patients treated with metoprolol received the drug both very early [0m[1;31m([0m[31mintra-venously[0m[1;31m)[0m[31m and during a subsequent [0m[1;31m3[0m[31m-month period, while placebo patients received no [0m
[31mbeta-blocker treatment for this period. The study thus was able to show a benefit from the overall metoprolol regimen but cannot separate the benefit of very early intravenous treatment from the [0m
[31mbenefit of later beta-blocker therapy. METOPROLOL TARTRATE: pharmacokinetics: Nonetheless, because the overall regimen showed a clear beneficial effect on survival without evidence of an early adverse[0m
[31meffect on survival, one acceptable dosage regimen is the precise regimen used in the trial. Because the specific benefit of very early treatment remains to be defined however, it is also reasonable to[0m
[31madminister the drug orally to patients at a later time as is recommended for certain other beta-blockers.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m4[0m[31m%  [0m[1;31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m23.2[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mBradycardia [0m[1;31m([0m[31mheart rate &lt;[0m[1;31m40[0m[31m beats/min[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m15.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m6.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m
[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> Second- or third-degree heart block  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> First-degree heart block [0m[1;31m([0m[31mP-R [0m
[31m&#x2265;[0m[1;31m0.26[0m[31m sec[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m5.3[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m1.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mHeart failure  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m27.5[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m29[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m6[0m[31m%  [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: precautions: PRECAUTIONS Risk of Anaphylactic Reactions While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may [0m
[31mbe more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. Information [0m
[31mfor Patients Advise patients to take metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose should be missed, the patient should take only the next [0m
[31mscheduled dose [0m[1;31m([0m[31mwithout doubling it[0m[1;31m)[0m[31m. Patients should not discontinue metoprolol without consulting the physician. METOPROLOL TARTRATE: precautions: Advise patients [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m to avoid operating automobiles [0m
[31mand machinery or engaging in other tasks requiring alertness until the patientâ€™s response to therapy with metoprolol has been determined; [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m to contact the physician if any difficulty in breathing [0m
[31moccurs; [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m to inform the physician or dentist before any type of surgery that he or she is taking metoprolol. Drug Interactions Catecholamine-depleting Drugs: Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., [0m
[31mreserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a catecholamine depletor for evidence [0m
[31mof hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. METOPROLOL TARTRATE: precautions: In addition, possibly significant hypertension may theoretically [0m
[31moccur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an irreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers [0m
[31mslow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Monitor heart rate and PR interval. Calcium Channel Blockers: Concomitant administration[0m
[31mof a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility because of negative chronotropic and inotropic effects. CYP2D6 Inhibitors: [0m
[31mPotent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor metabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in[0m
[31mplasma concentrations of metoprolol would decrease the cardioselectivity of metoprolol. METOPROLOL TARTRATE: drug_interactions: Known clinically significant potent inhibitors of CYP2D6 are [0m
[31mantidepressants such as fluvoxamine, fluoxetine, paroxetine, sertraline, bupropion, clomipramine, and desipramine; antipsychotics such as chlorpromazine, fluphenazine, haloperidol, and thioridazine; [0m
[31mantiarrhythmics such as quinidine or propafenone; antiretrovirals such as ritonavir; antihistamines such as diphenhydramine; antimalarials such as hydroxychloroquine or quinidine; antifungals such as [0m
[31mterbinafine. Hydralazine: Concomitant administration of hydralazine may inhibit presystemic metabolism of metoprolol leading to increased concentrations of metoprolol. METOPROLOL TARTRATE: [0m
[31mdrug_interactions: Alpha-adrenergic Agents: Antihypertensive effect of alpha-adrenergic blockers such as guanethidine, betanidine, reserpine, alpha-methyldopa or clonidine may be potentiated by [0m
[31mbeta-blockers including metoprolol. Beta-adrenergic blockers may also potentiate the postural hypotensive effect of the first dose of prazosin, probably by preventing reflex tachycardia. On the [0m
[31mcontrary, beta adrenergic blockers may also potentiate the hypertensive response to withdrawal of clonidine in patients receiving concomitant clonidine and beta-adrenergic blocker. If a patient is [0m
[31mtreated with clonidine and metoprolol concurrently, and clonidine treatment is to be discontinued, stop metoprolol several days before clonidine is withdrawn. Rebound hypertension that can follow [0m
[31mwithdrawal of clonidine may be increased in patients receiving concurrent beta-blocker treatment. METOPROLOL TARTRATE: drug_interactions: Drug Interactions Catecholamine-depleting Drugs: [0m
[31mCatecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a [0m
[31mcatecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. In addition, possibly significant hypertension may theoretically [0m
[31moccur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an irreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers [0m
[31mslow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Monitor heart rate and PR interval. METOPROLOL TARTRATE: drug_interactions: Calcium [0m
[31mChannel Blockers: Concomitant administration of a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility because of negative [0m
[31mchronotropic and inotropic effects. CYP2D6 Inhibitors: Potent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor [0m
[31mmetabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in plasma concentrations of metoprolol would decrease the cardioselectivity of metoprolol.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: precautions: In a [0m[1;31m21[0m[31m-month study in Swiss albino mice at three oral dosage levels of up to [0m[1;31m750[0m[31m mg/kg per day, benign lung tumors [0m[1;31m([0m[31msmall adenomas[0m[1;31m)[0m[31m occurred more frequently[0m
[31min female mice receiving the highest dose than in untreated control animals. There was no increase in malignant or total [0m[1;31m([0m[31mbenign plus malignant[0m[1;31m)[0m[31m lung tumors, or in the overall incidence of tumors or [0m
[31mmalignant tumors. This [0m[1;31m21[0m[31m-month study was repeated in CD-[0m[1;31m1[0m[31m mice, and no statistically or biologically significant differences were observed between treated and control mice of either sex for any type [0m
[31mof tumor. All mutagenicity tests performed [0m[1;31m([0m[31ma dominant lethal study in mice, chromosome studies in somatic cells, a Salmonella/mammalian-microsome mutagenicity test, and a nucleus anomaly test in [0m
[31msomatic interphase nuclei[0m[1;31m)[0m[31m were negative. Reproduction toxicity studies in mice, rats and rabbits did not indicate teratogenic potential for metoprolol tartrate. METOPROLOL TARTRATE: precautions: [0m
[31mEmbryotoxicity and/or fetotoxicity in rats and rabbits were noted starting at doses of [0m[1;31m50[0m[31m mg/kg in rats and [0m[1;31m25[0m[31m mg/kg in rabbits, as demonstrated by increases in preimplantation loss, decreases in the [0m
[31mnumber of viable fetuses per dose, and/or decreases in neonatal survival. High doses were associated with some maternal toxicity, and growth delay of the offspring in utero , which was reflected in [0m
[31mminimally lower weights at birth. The oral NOAELs for embryo-fetal development in mice, rats, and rabbits were considered to be [0m[1;31m25[0m[31m, [0m[1;31m200[0m[31m, and [0m[1;31m12.5[0m[31m mg/kg. This corresponds to dose levels that are [0m
[31mapproximately [0m[1;31m0.3[0m[31m, [0m[1;31m4[0m[31m, and [0m[1;31m0.5[0m[31m times, respectively, when based on surface area, the maximum human oral dose [0m[1;31m([0m[1;31m8[0m[31m mg/kg/day[0m[1;31m)[0m[31m of metoprolol tartrate. METOPROLOL TARTRATE: precautions: Metoprolol tartrate [0m
[31mhas been associated with reversible adverse effects on spermatogenesis starting at oral dose levels of [0m[1;31m3.5[0m[31m mg/kg in rats [0m[1;31m([0m[31ma dose that is only [0m[1;31m0.1[0m[31m-times the human dose, when based on surface area[0m[1;31m)[0m[31m, [0m
[31malthough other studies have shown no effect of metoprolol tartrate on reproductive performance in male rats. Pregnancy Category C Upon confirming the diagnosis of pregnancy, women should immediately [0m
[31minform the doctor. Metoprolol has been shown to increase postimplantation loss and decrease neonatal survival in rats at doses up to [0m[1;31m11[0m[31m times the maximum daily human dose of [0m[1;31m450[0m[31m mg, when based on [0m
[31msurface area. Distribution studies in mice confirm exposure of the fetus when metoprolol is administered to the pregnant animal. These limited animal studies do not indicate direct or indirect harmful[0m
[31meffects with respect to teratogenicity [0m[1;31m([0m[31msee Carcinogenesis, Mutagenesis, Impairment of Fertility [0m[1;31m)[0m[31m. METOPROLOL TARTRATE: precautions: There are no adequate and well-controlled studies in pregnant [0m
[31mwomen. The amount of data on the use of metoprolol in pregnant women is limited. The risk to the fetus/mother is unknown. Because animal reproduction studies are not always predictive of human [0m
[31mresponse, this drug should be used during pregnancy only if clearly needed. Nursing Mothers Metoprolol is excreted in breast milk in a very small quantity. An infant consuming [0m[1;31m1[0m[31m liter of breast milk [0m
[31mdaily would receive a dose of less than [0m[1;31m1[0m[31m mg of the drug. Fertility The effects of metoprolol on the fertility of human have not been studied. Metoprolol showed effects on spermatogenesis in male rats[0m
[31mat a therapeutic dose level, but had no effect on rates of conception at higher doses in animal fertility studies [0m[1;31m([0m[31msee Carcinogenesis, Mutagenesis, Impairment of Fertility [0m[1;31m)[0m[31m. Pediatric Use Safety and [0m
[31meffectiveness in pediatric patients have not been established. METOPROLOL TARTRATE: geriatric_use: Geriatric Use Clinical trials of metoprolol in hypertension did not include sufficient numbers of [0m
[31melderly patients to determine whether patients over [0m[1;31m65[0m[31m years of age differ from younger subjects in their response to metoprolol. Other reported clinical experience in elderly hypertensive patients [0m
[31mhas not identified any difference in response from younger patients. In worldwide clinical trials of metoprolol in myocardial infarction, where approximately [0m[1;31m478[0m[31m patients were over [0m[1;31m65[0m[31m years of age [0m[1;31m([0m[1;31m0[0m[31m [0m
[31mover [0m[1;31m75[0m[31m years of age[0m[1;31m)[0m[31m, no age-related differences in safety and effectiveness were found. Other reported clinical experience in myocardial infarction has not identified differences in response between[0m
[31mthe elderly and younger patients. However, greater sensitivity of some elderly individuals taking metoprolol cannot be categorically ruled out. Therefore, in general, it is recommended that dosing [0m
[31mproceed with caution in this population.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: package_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: brand_name         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: product_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_set_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions: Cardiovascular: In the randomized comparison of metoprolol and placebo described in the CLINICAL PHARMACOLOGY section, the following adverse reactions [0m
[31mwere reported: Metoprolol Placebo Hypotension [0m[1;31m([0m[31msystolic BP < [0m[1;31m90[0m[31m mmHg[0m[1;31m)[0m[31m [0m[1;31m27.4[0m[31m% [0m[1;31m23.2[0m[31m% Bradycardia [0m[1;31m([0m[31mheart rate <[0m[1;31m40[0m[31m beats/min[0m[1;31m)[0m[31m [0m[1;31m15.9[0m[31m% [0m[1;31m6.7[0m[31m% Second- or third-degree heart block [0m[1;31m4.7[0m[31m% [0m[1;31m4.7[0m[31m% First-degree heart [0m
[31mblock [0m[1;31m([0m[31mP-R â‰¥[0m[1;31m0.26[0m[31m sec[0m[1;31m)[0m[31m [0m[1;31m5.3[0m[31m% [0m[1;31m1.9[0m[31m% Heart failure [0m[1;31m27.5[0m[31m% [0m[1;31m29.6[0m[31m% Respiratory: Dyspnea of pulmonary origin has been reported in fewer than [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. Gastrointestinal: Nausea and abdominal pain have [0m
[31mbeen reported in fewer than [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. METOPROLOL TARTRATE: adverse_reactions: Dermatologic: Rash and worsened psoriasis have been reported, but a drug relationship is not clear. [0m
[31mMiscellaneous: Unstable diabetes and claudication have been reported, but a drug relationship is not clear. Potential Adverse Reactions A variety of adverse reactions not listed above have been [0m
[31mreported with other beta-adrenergic blocking agents and should be considered potential adverse reactions to metoprolol. Central Nervous System: Reversible mental depression progressing to catatonia; [0m
[31man acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on [0m
[31mneuropsychometrics. Cardiovascular: Intensification of AV block [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Hematologic: Agranulocytosis, nonthrombocytopenic purpura and thrombocytopenic purpura. METOPROLOL TARTRATE: [0m
[31madverse_reactions: Hypersensitive Reactions: Fever combined with aching and sore throat, laryngospasm and respiratory distress. Postmarketing Experience The following adverse reactions have been [0m
[31mreported during postapproval use of metoprolol: confusional state, an increase in blood triglycerides and a decrease in High Density Lipoprotein [0m[1;31m([0m[31mHDL[0m[1;31m)[0m[31m. Because these reports are from a population of [0m
[31muncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: dosage_and_administration: DOSAGE AND ADMINISTRATION Hypertension Individualized the dosage of metoprolol tartrate tablets. Metoprolol tartrate tablets should be taken [0m
[31mwith or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily in single or divided doses, whether used alone or added to a diuretic. Increase the dosage [0m
[31mat weekly [0m[1;31m([0m[31mor longer[0m[1;31m)[0m[31m intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after [0m[1;31m1[0m[31m week of therapy. The effective [0m
[31mdosage range of metoprolol tartrate tablets is [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg per day. Dosages above [0m[1;31m450[0m[31m mg per day have not been studied. METOPROLOL TARTRATE: dosage_and_administration: While once-daily dosing is [0m
[31meffective and can maintain a reduction in blood pressure throughout the day, lower doses [0m[1;31m([0m[31mespecially [0m[1;31m100[0m[31m mg[0m[1;31m)[0m[31m may not maintain a full effect at the end of the [0m[1;31m24[0m[31m-hour period, and larger or more [0m
[31mfrequent daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the[0m
[31mday. Beta [0m[1;31m1[0m[31m selectivity diminishes as the dose of metoprolol is increased. Angina Pectoris The dosage of metoprolol tartrate tablets should be individualized. Metoprolol tartrate tablets should be [0m
[31mtaken with or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily, given in two divided doses. Gradually increase the dosage at weekly intervals until [0m
[31moptimum clinical response has been obtained or there is pronounced slowing of the heart rate. METOPROLOL TARTRATE: dosage_and_administration: The effective dosage range of metoprolol tartrate tablets [0m
[31mis [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg per day. Dosages above [0m[1;31m400[0m[31m mg per day have not been studied. If treatment is to be discontinued, gradually decrease the dosage over a period of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m weeks [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mMyocardial Infarction Early Treatment During the early phase of definite or suspected acute myocardial infarction, initiate treatment with metoprolol tartrate tablets as soon as possible after the [0m
[31mpatient's arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patientâ€™s hemodynamic condition has stabilized. Begin treatment in this [0m
[31mearly phase with the intravenous administration of three bolus injections of [0m[1;31m5[0m[31m mg of metoprolol tartrate each; give the injections at approximately [0m[1;31m2[0m[31m-minute intervals. During the intravenous [0m
[31madministration of metoprolol, monitor blood pressure, heart rate, and electrocardiogram.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: product_type         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Metoprolol tartrate has been shown to reduce [0m[1;32m3[0m[32m-month mortality by [0m[1;32m36[0m[32m% in patients with suspected or definite myocardial infarction, suggesting a decrease in the risk of hospitalization for [0m
[32mthese patients. The study involved early treatment with metoprolol, both intravenously and orally, and demonstrated significant reductions in the incidence of ventricular fibrillation and chest pain [0m
[32mfollowing initial intravenous therapy. These effects were independent of the interval between the onset of symptoms and the initiation of therapy. However, the specific benefit of very early treatment[0m
[32mwith metoprolol compared to later treatment remains undefined. Therefore, while the overall regimen showed a clear beneficial effect on survival, the precise impact on hospitalization risk, especially[0m
[32mseparate from early intravenous treatment, is not explicitly detailed.[0m

[32mSOURCE: METOPROLOL TARTRATE label[0m
[32mEXTRACT_START_END: In a large [0m[1;32m([0m[1;32m1[0m[32m,[0m[1;32m395[0m[32m patients randomized[0m[1;32m)[0m[32m, double-blind, placebo-controlled clinical study, metoprolol was shown to reduce [0m[1;32m3[0m[32m-month mortality by [0m[1;32m36[0m[32m% [0m[32m...[0m[32m the benefit of later [0m
[32mbeta-blocker therapy.[0m
*[1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Metoprolol tartrate has been shown to reduce [0m[1;34m3[0m[34m-month [0m
[34mmortality by [0m[1;34m36[0m[34m% in patients with suspected or definite myocardial infarction, suggesting a decrease in the risk of hospitalization for these patients. The study involved early treatment with [0m
[34mmetoprolol, both intravenously and orally, and demonstrated significant reductions in the incidence of ventricular fibrillation and chest pain following initial intravenous therapy. These effects were[0m
[34mindependent of the interval between the onset of symptoms and the initiation of therapy. However, the specific benefit of very early treatment with metoprolol compared to later treatment remains [0m
[34mundefined. Therefore, while the overall regimen showed a clear beneficial effect on survival, the precise impact on hospitalization risk, especially separate from early intravenous treatment, is not [0m
[34mexplicitly detailed.[0m

[34mSOURCE: METOPROLOL TARTRATE label[0m
[34mEXTRACT_START_END: In a large [0m[1;34m([0m[1;34m1[0m[34m,[0m[1;34m395[0m[34m patients randomized[0m[1;34m)[0m[34m, double-blind, placebo-controlled clinical study, metoprolol was shown to reduce [0m[1;34m3[0m[34m-month mortality by [0m[1;34m36[0m[34m% [0m[34m...[0m[34m the benefit of later [0m
[34mbeta-blocker therapy.[0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that METOPROLOL TARTRATE has been shown to reduce 3-month mortality by 36% in patients with suspected or definite myocardial infarction, suggesting a decrease in the risk [0m
[32mof hospitalization for these patients."[0m[32m,[0m
[32m      [0m[32m"The study cited involved early treatment with METOPROLOL TARTRATE, both intravenously and orally, and demonstrated significant reductions in the incidence of ventricular fibrillation and chest [0m
[32mpain following initial intravenous therapy."[0m[32m,[0m
[32m      [0m[32m"However, the specific benefit of very early treatment with METOPROLOL TARTRATE compared to later treatment remains undefined, and the precise impact on hospitalization risk, especially separate[0m
[32mfrom early intravenous treatment, is not explicitly detailed in the information provided."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"METOPROLOL TARTRATE has been shown to reduce 3-month mortality in patients with suspected or definite myocardial infarction, which suggests a decrease in the risk of hospitalization for[0m
[32mthese patients. However, the precise impact on hospitalization risk, especially separate from early intravenous treatment, is not explicitly detailed."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does METOPROLOL TARTRATE increase or decrease the risk of hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that METOPROLOL TARTRATE has been shown to reduce 3-month mortality by 36% in patients with suspected or definite myocardial infarction, suggesting a decrease in the risk [0m
[34mof hospitalization for these patients."[0m[34m,[0m
[34m      [0m[34m"The study cited involved early treatment with METOPROLOL TARTRATE, both intravenously and orally, and demonstrated significant reductions in the incidence of ventricular fibrillation and chest [0m
[34mpain following initial intravenous therapy."[0m[34m,[0m
[34m      [0m[34m"However, the specific benefit of very early treatment with METOPROLOL TARTRATE compared to later treatment remains undefined, and the precise impact on hospitalization risk, especially separate[0m
[34mfrom early intravenous treatment, is not explicitly detailed in the information provided."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"METOPROLOL TARTRATE has been shown to reduce 3-month mortality in patients with suspected or definite myocardial infarction, which suggests a decrease in the risk of hospitalization for[0m
[34mthese patients. However, the precise impact on hospitalization risk, especially separate from early intravenous treatment, is not explicitly detailed."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does METOPROLOL TARTRATE increase or decrease the risk of hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that METOPROLOL TARTRATE has been shown to reduce [0m[1;31m3[0m[31m-month mortality by [0m[1;31m36[0m[31m% in patients with suspected or definite myocardial infarction, suggesting a decrease in the risk of [0m
[31mhospitalization for these patients.[0m
[1;31m3[0m[31m. The study cited involved early treatment with METOPROLOL TARTRATE, both intravenously and orally, and demonstrated significant reductions in the incidence of ventricular fibrillation and chest pain[0m
[31mfollowing initial intravenous therapy.[0m
[1;31m4[0m[31m. However, the specific benefit of very early treatment with METOPROLOL TARTRATE compared to later treatment remains undefined, and the precise impact on hospitalization risk, especially separate [0m
[31mfrom early intravenous treatment, is not explicitly detailed in the information provided.[0m
[31m        -----[0m
[31m        Final answer: METOPROLOL TARTRATE has been shown to reduce [0m[1;31m3[0m[31m-month mortality in patients with suspected or definite myocardial infarction, which suggests a decrease in the risk of [0m
[31mhospitalization for these patients. However, the precise impact on hospitalization risk, especially separate from early intravenous treatment, is not explicitly detailed.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided seems sound and consistent with medical knowledge. The user has correctly interpreted the information from FDAHandler regarding the effect of METOPROLOL [0m
[32mTARTRATE on mortality in the context of myocardial infarction and has appropriately qualified the limitations of the data regarding the specific impact on hospitalization risk. There are no apparent [0m
[32mflaws in the reasoning process."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided seems sound and consistent with medical knowledge. The user has correctly interpreted the information from FDAHandler regarding the effect of METOPROLOL [0m
[34mTARTRATE on mortality in the context of myocardial infarction and has appropriately qualified the limitations of the data regarding the specific impact on hospitalization risk. There are no apparent [0m
[34mflaws in the reasoning process."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided seems sound and consistent with medical knowledge. The user has correctly interpreted the information from FDAHandler regarding the effect of METOPROLOL [0m
[31mTARTRATE on mortality in the context of myocardial infarction and has appropriately qualified the limitations of the data regarding the specific impact on hospitalization risk. There are no apparent [0m
[31mflaws in the reasoning process.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of hospitalization?"[0m[32m is that METOPROLOL TARTRATE has been shown to reduce [0m[1;32m3[0m[32m-month mortality by [0m[1;32m36[0m[32m% in patients [0m
[32mwith suspected or definite myocardial infarction, which suggests a decrease in the risk of hospitalization for these patients. However, the precise impact on hospitalization risk, especially separate [0m
[32mfrom early intravenous treatment, is not explicitly detailed.[0m
